Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Antimicrobial pharmacodynamics.
Ambrose PG Jr, Owens RC, Grasela D. Ambrose PG Jr, et al. Med Clin North Am. 2000 Nov;84(6):1431-46. doi: 10.1016/s0025-7125(05)70296-0. Med Clin North Am. 2000. PMID: 11155851
Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.
Rubino CM, Ambrose P, Cirincione B, Arguedas A, Sher L, Lopez E, Sáez-Llorens X, Grasela DM. Rubino CM, et al. Diagn Microbiol Infect Dis. 2007 Sep;59(1):67-74. doi: 10.1016/j.diagmicrobio.2007.04.015. Diagn Microbiol Infect Dis. 2007. PMID: 17875453 Clinical Trial.
Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756.
Gajjar DA, Sukoneck SC, Bello A, Ge Z, Christopher L, Grasela DM. Gajjar DA, et al. Pharmacotherapy. 2002 Feb;22(2):160-5. doi: 10.1592/phco. Pharmacotherapy. 2002. PMID: 11837554 Clinical Trial.
Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z, Grasela DM, Krishna G. Wang Z, et al. Clin Ther. 2007 Jun;29(6):1098-106. doi: 10.1016/j.clinthera.2007.06.015. Clin Ther. 2007. PMID: 17692724 Clinical Trial.
Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.
LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. LaCreta FP, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):59S-66S. doi: 10.1592/phco.20.8.59s.35183. Pharmacotherapy. 2000. PMID: 10850522 Clinical Trial.
Age and gender effects on the pharmacokinetics of gatifloxacin.
LaCreta FP, Kollia GD, Duncan G, Behr D, Grasela DM. LaCreta FP, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):67S-75S. doi: 10.1592/phco.20.8.67s.35185. Pharmacotherapy. 2000. PMID: 10850523
Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM, Christofalo B, Kollia GD, Duncan G, Noveck R, Manning JA Jr, LaCreta FP. Grasela DM, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):87S-94S. doi: 10.1592/phco.20.8.87s.35187. Pharmacotherapy. 2000. PMID: 10850525
Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.
Gajjar DA, LaCreta FP, Kollia GD, Stolz RR, Berger S, Smith WB, Swingle M, Grasela DM. Gajjar DA, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):76S-86S. doi: 10.1592/phco.20.8.76s.35182. Pharmacotherapy. 2000. PMID: 10850524 Clinical Trial.
A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.
Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, Grasela DM. Gajjar DA, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):49S-58S. doi: 10.1592/phco.20.8.49s.35186. Pharmacotherapy. 2000. PMID: 10850521 Clinical Trial.
69 results
Jump to page